An Integrated In Vitro and In Vivo High-Throughput Screen Identifies Treatment Leads for Ependymoma
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Summary Using a mouse model of ependymoma—a chemoresistant brain tumor—we combined multi-cell high-throughput screening (HTS), kinome-wide binding assays, and in vivo efficacy studies, to identify potential treatments with predicted toxicity against neural stem cells (NSC). We identified kinases within the insulin signaling pathway and centrosome cycle as regulators of ependymoma cell proliferation, and their corresponding inhibitors as potential therapies. FDA approved drugs not currently used to treat ependymoma were also identified that posses selective toxicity against ependymoma cells relative to normal NSCs both in vitro and in vivo e.g., 5-fluoruracil. Our comprehensive approach advances understanding of the biology and treatment of ependymoma including the discovery of several treatment leads for immediate clinical translation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
5-Fluorouracil: mechanisms of action and clinical strategies
Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1074 · Cited by 5,332 · cited 2×
“The ependymoma-selective activity of 5-FU in our HTS and relatively low expression of TYMS (Figure 5C) —the principal cellular target of 5-FU—in mEP cells, suggest this drug as a rational treatment of cerebral ependymoma (Longley et al., 2003).”
A cell initiating human acute myeloid leukaemia after transplantation into SCID mice
Lapidot, T., Sirard, C., Vormoor, J., Murdoch, B., Hoang, T., Caceres-Cortes, J., Minden, M., Paterson, B., Caligiuri, M. A., & Dick, J. E. (1994) · Nature · doi:10.1038/367645a0 · Cited by 4,783 · cited 1×
“Recent evidence suggests that some cancers, including ependymomas, contain stem-like cancer cells that are both sufficient and required to propagate the disease (Johnson et al., 2010; Lapidot et al., 1994; Singh et al., 2004; Taylor et al., 2005).”
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256 · cited 2×
“, colorectal cancer (Douillard et al., 2000; IMPACT, 1995), but this drug has not been tested formally in patients with ependymoma.”
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632 · cited 2×
“Similarly, bortezomib—a reversible inhibitor of the 26S proteasome—has not been tested against ependymoma in the clinic but was highly potent against mEP cells, and has activity against a variety of cancers including brain tumors (Adams, 2004; Phuphanich et al., 2010; Richardson et al., 2003; Taniguchi et al., 2009).”
The Glial Nature of Embryonic and Adult Neural Stem Cells
Kriegstein, A., & Alvarez-Buylla, A. (2009) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.051508.135600 · Cited by 2,475 · cited 2×
“To provide an additional measure of the cellular response to drugs we used Prom1 mice in our studies: these mice express the LacZ reporter from the Prom1 locus in NSCs, neuroblasts, and ependymal cells (Coskun et al., 2008; Kriegstein and Alvarez-Buylla, 2009; Zhu et al., 2009).”
Shared and separate functions of polo-like kinases and aurora kinases in cancer
Lens, S. M. A., Voest, E. E., & Medema, R. H. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2964 · Cited by 597 · cited 1×
“…and PLK1 inhibitors, of which more than 18 are currently in Phase I or II clinical trial, are attractive candidates for ependymoma clinical trials (Lens et al., 2010; (C) ROC analyses showing the true (y axis) versus false (x axis) positive rates of p curves in gray are calculated from 200…”
Jin, K., Wang, X., Xie, L., Mao, X. O., & Greenberg, D. A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000154107 · Cited by 225
Cited by
Challenges to curing primary brain tumours
Aldape, K., Brindle, K. M., Chesler, L., Chopra, R., Gajjar, A., Gilbert, M. R., Gottardo, N., Gutmann, D. H., Hargrave, D., Holland, E. C., et al. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0177-5 · Cited by 959
Self-citationNeuroblastoma: developmental biology, cancer genomics and immunotherapy
Cheung, N.-K. V., & Dyer, M. A. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3526 · Cited by 801
C11orf95–RELA fusions drive oncogenic NF-κB signalling in ependymoma
Parker, M., Mohankumar, K. M., Punchihewa, C., Weinlich, R., Dalton, J. D., Li, Y., Lee, R., Tatevossian, R. G., Phoenix, T. N., Thiruvenkatam, R., et al. (2014) · Nature · doi:10.1038/nature13109 · Cited by 670
Self-citationEpigenomic alterations define lethal CIMP-positive ependymomas of infancy
Mack, S. C., Witt, H., Piro, R. M., Gu, L., Zuyderduyn, S., Stütz, A. M., Wang, X., Gallo, M., Garzia, L., Zayne, K., et al. (2014) · Nature · doi:10.1038/nature13108 · Cited by 607
Sachlos, E., Risueño, R. M., Laronde, S., Shapovalova, Z., Lee, J.-H., Russell, J., Malig, M., McNicol, J. D., Fiebig-Comyn, A., Graham, M., et al. (2012) · Cell · doi:10.1016/j.cell.2012.03.049 · Cited by 456
Metadata
- Authors
- Atkinson, J. M., Shelat, A. A., Carcaboso, A. M., Kranenburg, T. A., Arnold, L. A., Boulos, N., Wright, K., Johnson, R. A., Poppleton, H., Mohankumar, K. M., Féau, C., Phoenix, T., Gibson, P., Zhu, L., Tong, Y., Eden, C., Ellison, D. W., Priebe, W., Koul, D., Yung, W. K. A., Gajjar, A., Stewart, C. F., Guy, R. K., & Gilbertson, R. J.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2011-09
- Volume
- 20
- Issue
- 3
- Pages
- 384-399
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2027313027
- Cited by
- 117
- References
- 7
- FWCI
- 5.49
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.